---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000078"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-30T00:08:19.636733+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific completes $3.7B acquisition of Axonics; enters sacral neuromodulation market

## Summary
- Purchase price $71/share, equity value $3.7B, enterprise value $3.3B net of cash.
- Deal expected to be immaterial to adjusted EPS in 2024-2025, accretive thereafter.
- Adds Axonics' sacral neuromodulation portfolio for urinary/bowel dysfunction to Urology unit.
- GAAP basis less accretive due to amortization and acquisition-related charges.

## SEC filing metadata
- accession: 0000885725-24-000078
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000078/0000885725-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000078/bsx-20241115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000078
- JSON: https://secwatch.observer/filing/0000885725-24-000078.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.